Completed PHASE3 INTERVENTIONAL 3-arm NCT00075829

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)

A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)

Sponsor: Blood and Marrow Transplant Clinical Trials Network

Conditions Multiple Myeloma

Interventions Dexamethasone Non-Myeloablative Allogeneic Transplant Observation One Autologous Transplant Second Autologous Transplant Thalidomide

Updated 9 times since 2017 Last updated: Oct 19, 2021 Started: Dec 31, 2003 Primary completion: Jun 30, 2012 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Multiple Myeloma, this trial is completed. The trial is conducted by Blood and Marrow Transplant Clinical Trials Network and has accumulated 9 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Dec 2021 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Blood and Marrow Transplant Clinical Trials Network
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
National Marrow Donor Program

Data source: National Heart, Lung, and Blood Institute (NHLBI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Birmingham, United States , Boston, United States , Cincinnati, United States , Cleveland, United States , Denver, United States , Duarte, United States , Durham, United States , Gainesville, United States and 21 more locations